Quick Answer
RxSight, Inc. reported R&D Expense of $38.55 million for fiscal year 2025.
RxSight, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $38.55M | +12.2% |
| 2024 | $34.37M | +18.3% |
| 2023 | $29.05M | +11.8% |
| 2022 | $25.98M | +6.0% |
| 2021 | $24.50M | +11.7% |
| 2020 | $21.93M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.06M | +2.5% | -11.3% |
| June 30, 2025 | $10.22M | +23.2% | -1.4% |
| March 31, 2025 | $10.37M | +29.1% | +17.3% |
| September 30, 2024 | $8.84M | +24.5% | +6.6% |
| June 30, 2024 | $8.29M | +12.0% | +3.2% |
| March 31, 2024 | $8.03M | +11.4% | +13.1% |
| September 30, 2023 | $7.10M | +11.2% | -4.1% |
| June 30, 2023 | $7.40M | +19.5% | +2.7% |
- RxSight, Inc. showed an increase of +12.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, RxSight, Inc.’s r&d expense has grown by 75.7% (from $21.93 million to $38.55 million).
- The most recent figure is from RxSight, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: